UNSPSC 51271627: Etidocaine hydrochloride

This classification denotes an anesthetic agent with the molecular formula C17H28N2O.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier G6N3B3U8E6, chemically known as 2,6-butyroxylidide, 2-(n-ethylpropylamino)-, hydrochloride, (+-)- but more generally known as etidocaine hydrochloride, which bears US NIH Compound Identifier 37498. European Medicines Agency schedules Etidocaine hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB02037MIG.

Most nations, for tariff and trade purposes, schedule etidocaine hydrochloride under HS 29242995 and SITC 51479. As of Q4 2014, ETIDOCAINE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Etidocaine hydrochloride bears US NLM identifiers UMLS ID C0733377 and NCI Concept Code C77325. SMILES: CCCN(CC)C(CC)C(=O)NC1C(CCCC1C)C.CL.

UNSPSC 51271627 Etidocaine hydrochloride is a Commodity code covering a local anesthetic injectable pharmaceutical product that state and local health systems, correctional facilities, and emergency medical services procure for surgical, dental, and pain-management procedures. The code reflects procurement of a specific branded or generic pharmaceutical formulation rather than a broad service family. State and local governments acquire etidocaine hydrochloride primarily through standing pharmaceutical supply contracts, health system formulary agreements, and emergency medical supply channels; usage patterns are driven by clinical protocols at individual facilities rather than centralized or regional standardization.

The recent-opportunities block provided no documented state or local solicitations under this code. Without active RFP, RFQ, IFB, or ITB records in the source material, geographic activity and issuing-body concentration cannot be characterized from current procurement signals. Pharmaceutical procurement at the state and local level often flows through group purchasing organizations, cooperative contracts managed by state health departments or purchasing consortia, or direct vendor relationships with health systems rather than through published competitive solicitations, which may explain the absence of recent posted opportunities under this specific drug code.